HUTCHMED

London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen

Final Results for the year ended 31 December 2012

Chi-Med and Nestlé Health Science establish Joint Venture

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib

Interim Results for the Six Months Ended 30 June 2012

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook

Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib

Interim Results for the Six Months Ended 30 June 2011

China Healthcare Division expands OTC drug distribution and marketing operations

Final Results for the year ended 31 December 2010 Strong performance across all divisions.

Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.

Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer

Seven-year extension of IP protection for Chi-Med's main prescription drug

Final Results for the year ended 31 December 2009

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases

Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%

Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia

Chi-Med's Main Drugs Included in the New National Essential Medicines List

Interim Results for the Six Months Ended 30 June 2009

Patient Enrolment Completed Ahead of Schedule for the Global Phase IIb Ulcerative Colitis Trial of HMPL-004

Phase II Crohn's Disease Trial for HMPL-004 Delivers Encouraging Results

Final Results for the year ended 31 December 2008

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn's Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

HMPL-002 Clinical Update

Hutchison MediPharma Limited Enters into Drug Discovery and Development Partnership With Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Chi-Med Expands Drug Discovery and Development Partnership With Lilly

Hutchison MediPharma wins the 2008 American College of Gastroenterology International Award

Interim Results for the Six Months Ended 30 June 2008

China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture

Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores

Preliminary Results for the year ended 31 December 2007

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

Strong growth in China Healthcare divisionStreamlining of product range set to further improve financial performance

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company

Interim Results for the Six Months Ended 30 June 2007

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility

Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China

Preliminary Results for the year ended 31 December 2006